{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:17:40Z","timestamp":1771654660975,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":117,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100570","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T08:04:16Z","timestamp":1651305856000},"page":"100570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Michelle","family":"Bradbury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Akurang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmanjatinder S","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100570_bib0001","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2017.7312","article-title":"Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma","author":"Sun","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctarc.2022.100570_bib0002","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2021. Toronto, ON: Canadian Cancer Society; 2021."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100570_bib0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40644-019-0236-2","article-title":"Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings","volume":"19","author":"Nie","year":"2019","journal-title":"Cancer Imaging"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100570_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100570_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42047-018-0013-8","article-title":"Pulmonary mucinous adenocarcinomas: a clinicopathologic series with emphasis on the prognostic significance of spread through alveolar spaces, and presence of solid growth component","volume":"1","author":"Paulk","year":"2018","journal-title":"Surg Exp Pathol"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100570_bib0006","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1038\/s41598-018-24540-7","article-title":"Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study","volume":"8","author":"Xie","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100570_bib0007","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s13277-015-3869-1","article-title":"Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study","volume":"37","author":"Qu","year":"2016","journal-title":"Tumor Biol"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100570_bib0008","doi-asserted-by":"crossref","first-page":"508","DOI":"10.21037\/tlcr.2017.06.10","article-title":"Biology of invasive mucinous adenocarcinoma of the lung","volume":"6","author":"Cha","year":"2017","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.ctarc.2022.100570_bib0009","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100570_bib0010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/JTO.0b013e3181d60ff5","article-title":"A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice","volume":"5","author":"Casali","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100570_bib0011","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2353\/jmoldx.2007.060182","article-title":"Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features","volume":"9","author":"Finberg","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctarc.2022.100570_bib0012","unstructured":"Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics: A 2020 special report on lung cancer. Toronto, ON: Canadian Cancer Society; 2020."},{"key":"10.1016\/j.ctarc.2022.100570_bib0013","article-title":"Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement","author":"Kim","year":"2021","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100570_bib0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100570_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/curroncol28010008","article-title":"Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer","volume":"28","author":"Stock-Martineau","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctarc.2022.100570_bib0016","first-page":"1","article-title":"Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world","volume":"00","author":"Shokoohi","year":"2021","journal-title":"Cancer Medicine"},{"issue":"8","key":"10.1016\/j.ctarc.2022.100570_bib0017","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/JTO.0b013e3181e2a2bc","article-title":"Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma","volume":"5","author":"Hata","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctarc.2022.100570_bib0018","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-021-03609-3","article-title":"Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung","author":"Ueda","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctarc.2022.100570_bib0019","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/PAS.0000000000000246","article-title":"Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation","volume":"38","author":"Kadota","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctarc.2022.100570_bib0020","first-page":"95","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","author":"Kerr","year":"2019","journal-title":"J Lung Can"},{"issue":"15","key":"10.1016\/j.ctarc.2022.100570_bib0021","article-title":"Prevalence of ALK mutations in advanced NSCLC patients in the United States: Analysis with a real-world oncology database","volume":"38","author":"Allen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2022.100570_bib0022","doi-asserted-by":"crossref","unstructured":"Letovanec I, Finn S, Zygoura P, et\u00a0al. Evaluation of NGS and RT-PCR Methods for ALK Rearrangements in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2018;13(3):413-425. Doi:10.1016\/j.jtho.2017.11.117.","DOI":"10.1016\/j.jtho.2017.11.117"},{"issue":"8","key":"10.1016\/j.ctarc.2022.100570_bib0023","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctarc.2022.100570_bib0024","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1 -Rearranged Non\u2013Small-Cell Lung Cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100570_bib0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100570_bib0026","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/2159-8290.CD-17-1004","article-title":"Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers","volume":"8","author":"Smith","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:01Z","timestamp":1762842901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":26,"alternative-id":["S2468294222000600"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100570","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100570"}}